Epizyme, Inc. to Present at Piper Jaffray Conference on December 1, 2015

CAMBRIDGE, Mass.--()--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, will participate in the Piper Jaffray 27th Annual Healthcare Conference at the Lotte Palace Hotel in New York on Tuesday, December 1 at 1pm ET.

A live webcast and archived replay for the conference will be available by visiting the Investor Center of the Epizyme website at www.epizyme.com.

About Epizyme, Inc.

Epizyme, Inc. is a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of chromatin modifying proteins (CMPs), such as histone methyltransferases or HMTs. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Contacts

Epizyme, Inc.
Andrew Singer, 617-500-0712
Executive Vice President and Chief Financial Officer
asinger@epizyme.com
or
Media/Investors:
THRUST Investor Relations
Monique Allaire, 617-895-9511
monique@thrustir.com

Contacts

Epizyme, Inc.
Andrew Singer, 617-500-0712
Executive Vice President and Chief Financial Officer
asinger@epizyme.com
or
Media/Investors:
THRUST Investor Relations
Monique Allaire, 617-895-9511
monique@thrustir.com